Dr. Christopher Schaber, President and CEO of Soligenix, a company developing drug therapies in rare diseases and areas of unmet medical need, including a treatment for oral mucositis in head and neck […]
CEL-SCI Corporation recently announced that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy, Multikine. The accrual and treatment phases of […]
Novocure is an oncology company working to develop a novel cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid […]
TapImmune Inc., a Florida-based leading clinical-stage immuno-oncology company recently announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for […]
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. They currently have an innovative and […]
Altor BioScience is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and viral infections, based on its engineered cytokine technology platforms. It was formed in 2002 by Dr. […]
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief […]
Dr. Anthony Gringeri, President and CEO of Immunocellular Therapeutics, a company developing immune-based therapies for the treatment of cancer, is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells […]
